92 related articles for article (PubMed ID: 445608)
41. [Polychemotherapy in patients with ovarian cancer].
Kotova DG; Nechaeva ID; Vinokurov VL; Zel'dovich DR; Khasanova DT
Vopr Onkol; 1980; 26(6):7-11. PubMed ID: 7385734
[TBL] [Abstract][Full Text] [Related]
42. [Method for determination of non-protein nitrogen constituents, uric acid; a review and methods for determination (author's transl)].
Nakayama T
Rinsho Byori; 1975 Jun; Suppl 22():53-71. PubMed ID: 802846
[No Abstract] [Full Text] [Related]
43. [The prognostic value of raised uric acid in the blood in arterial hypertension in pregnancy. 58 cases (author's transl)].
Dequiedt P; Tacquet A; Puech F; Cotteel M; Potier A; Leroy JL; Delecour M
J Gynecol Obstet Biol Reprod (Paris); 1979 Mar; 8(2):115-20. PubMed ID: 479519
[TBL] [Abstract][Full Text] [Related]
44. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
45. [Combination of chemotherapy of malignant tumours, BCG vaccination with in particular of the ovaries (author's transl)].
Lédr J
Cesk Gynekol; 1974 Mar; 39(2):142-3. PubMed ID: 4452013
[No Abstract] [Full Text] [Related]
46. [Prediction of the clinical response of ovarian cancer to chemotherapy using an in vitro anticancer drug sensitivity test].
Li ZX
Zhonghua Fu Chan Ke Za Zhi; 1988 Sep; 23(5):287-9, 318. PubMed ID: 3250811
[No Abstract] [Full Text] [Related]
47. Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.
Markman M; Kennedy A; Kim J
Gynecol Oncol; 2001 Dec; 83(3):593-5. PubMed ID: 11733977
[TBL] [Abstract][Full Text] [Related]
48. [Chemotherapy of cancer and alteration of body fluid constituents--evaluation of the treatment of cancer].
Hiraki K; Kimura I; Asano K; Karvanishi K; Sezaki T
Gan No Rinsho; 1969 Jun; 15(6):528-33. PubMed ID: 5390397
[No Abstract] [Full Text] [Related]
49. Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer.
Wimberger P; Heubner M; Lindhofer H; Jäger M; Kimmig R; Kasimir-Bauer S
Anticancer Res; 2009 May; 29(5):1787-91. PubMed ID: 19443405
[TBL] [Abstract][Full Text] [Related]
50. [Serum uric-acid and serum lipids. Statistical correlations. Report of 1 000 cases (author's transl)].
Bouvenot G; Bartolin R; Sciara M; Delboy C; Arnaud C
Sem Hop; 1980 Feb 8-15; 56(5-6):263-4. PubMed ID: 6243798
[TBL] [Abstract][Full Text] [Related]
51. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Markman M
Gynecol Oncol; 2009 Jul; 114(1):136-7; authore reply 137. PubMed ID: 19138792
[No Abstract] [Full Text] [Related]
52. Survival of patients with advanced ovarian carcinoma treated with Penberol.
Novotná J; Andrysek O; Kobilková J; Laurová L
Neoplasma; 1983; 30(2):245-50. PubMed ID: 6302531
[TBL] [Abstract][Full Text] [Related]
53. [Hyperuricemia in chronic alcoholism (author's transl)].
Miko M; Jajić I; Degmecić M; Petö S
Lijec Vjesn; 1977 May; 99(5):293-5. PubMed ID: 886904
[No Abstract] [Full Text] [Related]
54. [Results of in vitro culturing of ovarian neoplasms and testing with cytostatic agents].
Spitzbart H; Schmidt F
Zentralbl Gynakol; 1970 Feb; 92(7):201-5. PubMed ID: 5516074
[No Abstract] [Full Text] [Related]
55. [Second-line chemotherapy of ovarian cancer].
de Gramont A; Drolet Y; Lavoie A; Painchaud M; Blouin R; Tessier C; Ouellet P
Union Med Can; 1984 Nov; 113(11):940-2. PubMed ID: 6516049
[No Abstract] [Full Text] [Related]
56. Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers.
George MJ; Heron JF; Kerbrat P; Chauvergne J; Goupil A; Lebrun D; Guastalla JP; Namer M; Bugat R; Ayme Y
Semin Oncol; 1989 Apr; 16(2 Suppl 4):30-2. PubMed ID: 2652318
[No Abstract] [Full Text] [Related]
57. [Automatic determination of triglyceride, cholesterol, glucose and serum uric acid in the screening for preventive medicine (author's transl)].
Morisi G; Macchia T; Angelico F; Pacioni F; Zucca A
Ann Ist Super Sanita; 1979; 15(2):239-61. PubMed ID: 554486
[TBL] [Abstract][Full Text] [Related]
58. [Genetical and epidemiological study of uricaemia in a Pyrenean population. (Region of Sault - Pyrérées audoises) (author's transl)].
Bonaiti C; Constans J; Valdiguié P
Rev Epidemiol Sante Publique; 1976; 24(6):469-78. PubMed ID: 1023280
[TBL] [Abstract][Full Text] [Related]
59. [Combined chemo-hormone therapy in advanced ovarian cancer. Results of the 2d Austrian ovarian cancer study].
Sevelda P
Gynakol Rundsch; 1990; 30 Suppl 1():57-61. PubMed ID: 2150399
[No Abstract] [Full Text] [Related]
60. Phase II clinical trial of diaziquone in the treatment of patients with epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Slayton RE; Blessing JA; Sutton GP; Homesley HD; Park R
Cancer Treat Rep; 1986 Feb; 70(2):309-10. PubMed ID: 3948196
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
